Compare Merck & Co., Inc. (MRK) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vital Farms Inc — how do they compare? Merck & Co., Inc. trades at $132.77 (market cap $321.77B), while Vital Farms Inc trades at $11.49 (market cap $496.50M). The key difference: Merck & Co., Inc. is far larger — about 648.1× Vital Farms Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| MRK | VITL | |
|---|---|---|
Market Cap | $321.77B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $131.84 | $52.41 |
52-Week Low | $77.60 | $8.28 |
Enterprise Value | $368.53B | $583.51M |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
VITL trades at $11.35, down 0.8% daily, with a bearish technical signal driven by moving averages. Recent Q2 2026 results showed a loss of $0.47 per share, beating expectations but reflecting revenue declines amid industry oversupply challenges. The company secured a $125 million term loan in August 2026 to bolster liquidity, as net cash flow remained negative. Valuation ratios like P/E of 11.77 and P/S of 0.67 suggest potential undervaluation, but profitability metrics are weak with net income margin at 0.02%.
The outlook is mixed: analyst consensus is bullish with a $13.00 price target, but execution risks from cost pressures and competitive gaps persist. Near-term catalysts include Q3 2026 earnings, while downside risks involve ongoing operational challenges and class-action litigation noted in May 2026. The stock's proximity to its 52-week low underscores cautious sentiment despite institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
